Abstract
Synthetic small interfering RNAs (siRNAs) open promising new therapeutic perspectives in acute and chronic pathologies. A number of experiments in mice demonstrated the ability of naked siRNAs injected under a normal pressure to trigger gene silencing in vivo, translating into a measurable phenotype. We focus in this review on the information that we can gain from these experiments, and discuss how the specificity of the gene silencing in vivo can be controlled. Because the activity of most drugs increases with the dosing, we are prone to consider that increasing the concentration of siRNAs within cells enhances the efficiency and the duration of the silencing. However, because RNAi is a saturable process, and because increasing the siRNA concentration into cells can induce undesirable side effects, this must be demonstrated. We compare in this review the methods used to quantify and study the biodistribution of siRNAs in living animals, and discuss how these methods can help in designing for each model and each siRNA the most adequate protocol to silence a cognate target gene in vivo.
Current Topics in Medicinal Chemistry
Title: Systemic Delivery and Quantification of Unformulated Interfering RNAs In Vivo
Volume: 9 Issue: 12
Author(s): Aurelie Morin, Catherine Gallou-Kabani, Jacques R.R. Mathieu and Florence Cabon
Affiliation:
Abstract: Synthetic small interfering RNAs (siRNAs) open promising new therapeutic perspectives in acute and chronic pathologies. A number of experiments in mice demonstrated the ability of naked siRNAs injected under a normal pressure to trigger gene silencing in vivo, translating into a measurable phenotype. We focus in this review on the information that we can gain from these experiments, and discuss how the specificity of the gene silencing in vivo can be controlled. Because the activity of most drugs increases with the dosing, we are prone to consider that increasing the concentration of siRNAs within cells enhances the efficiency and the duration of the silencing. However, because RNAi is a saturable process, and because increasing the siRNA concentration into cells can induce undesirable side effects, this must be demonstrated. We compare in this review the methods used to quantify and study the biodistribution of siRNAs in living animals, and discuss how these methods can help in designing for each model and each siRNA the most adequate protocol to silence a cognate target gene in vivo.
Export Options
About this article
Cite this article as:
Morin Aurelie, Gallou-Kabani Catherine, Mathieu R.R. Jacques and Cabon Florence, Systemic Delivery and Quantification of Unformulated Interfering RNAs In Vivo, Current Topics in Medicinal Chemistry 2009; 9 (12) . https://dx.doi.org/10.2174/156802609789630820
DOI https://dx.doi.org/10.2174/156802609789630820 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy Metal Complexes with Aromatic N-Containing Ligands as Potential Agents in Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Advances in Efficient Health Communication: Promoting Prevention and Detection of STDs
Current HIV Research Molecular Mistletoe Therapy: Friend or Foe in Established Anti-Tumor Protocols? A Multicenter, Controlled, Retrospective Pharmaco-Epidemiological Study in Pancreas Cancer
Current Molecular Medicine Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Apoptosis Pathway with Natural Terpenoids: Implications for Treatment of Breast and Prostate Cancer
Current Drug Targets Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Revision of the Synthesis and Pharmacological Activity of a Reported Translation Inhibitor
Anti-Cancer Agents in Medicinal Chemistry Structural Aspects of Peptides with Immunomodulating Activity
Mini-Reviews in Medicinal Chemistry PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Keto and Exomethylene Pyranonucleosides as Antitumor Agents
Mini-Reviews in Medicinal Chemistry Genetic Modification of Natural Killer Cells for Leukemia Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Eph/ephrin Signaling as a Potential Therapeutic Target After Central Nervous System Injury
Current Pharmaceutical Design The Possible Role of Saponin in Type-II Diabetes- A Review
Current Diabetes Reviews The Effects of All-Trans-Retinoic Acid on Cell Cycle and Alkaline Phosphatase Activity in Pancreatic Cancer Cells
Medicinal Chemistry Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy
Current Medicinal Chemistry The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers
Current Cancer Drug Targets